Regulatory Guidance forDeveloping Technologies.

Our attorneys bring deep healthcare and FDA regulatory knowledge to the questions that arise as technology reshapes how care is delivered, how health data moves, and how products reach the market.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts

DOJ Revives Targeted Second Requests for Merger Review

Alerts

Delaware Court of Chancery Issues First Decision Addressing Public Benefit Corporations

News Articles

Weiheng Chen Named Finalist for 2026 ALB Hong Kong Law Awards

Leading Matters

Client Highlights

Wilson Sonsini Advises Dili on $15 Million Series A Led by Khosla Ventures

On July 30, 2026, Dili, an AI compliance company, announced it has raised $15 million in Series A funding. The round was led by Khosla Ventures, with participation from Allianz, Rebel Fund, Brick and Mortar Ventures' Darren Bechtel, and Y Combinator's Garry Tan. Wilson Sonsini Goodrich & Rosati advised Dili on the transaction.

Learn More

Client Highlights

Firm Advises Secturion Systems on Acquisition by Carlyle Group

On July 27, 2026, global investment firm Carlyle announced that it had acquired Secturion Systems, a leading provider of high-speed, NSA-certified hardware encryption solutions that protect sensitive and classified information. The transaction marks the first investment by Carlyle’s dedicated middle-market Aerospace, Defense & Government, and Industrials platform. Wilson Sonsini Goodrich & Rosati advised Secturion on the transaction.

Learn More

Client Highlights

Firm Advises Lead Investor G2 Venture Partners and Eclipse on Antora Energy’s $500 Million Series C

On July 30, 2026, Antora Energy, a leading U.S. energy storage company, announced its closing on $550 million in Series C funding co-led by G2 Venture Partners and Eclipse, with participation from existing and new investors. Wilson Sonsini Goodrich & Rosati advised G2 Venture Partners and Eclipse on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises DroneDeploy on $845 Million Acquisition by Procore Technologies

On July 29, 2026, Procore Technologies, a global provider of construction management software, announced it has entered into a definitive agreement to acquire DroneDeploy, a robotics and visual intelligence platform. Procore will acquire DroneDeploy for approximately $845 million in cash, subject to customary purchase price adjustments. Wilson Sonsini Goodrich & Rosati is advising DroneDeploy on the transaction

Learn More

Client Highlights

Wilson Sonsini Advises Oak Hill Bio on IP Matters in Proposed Business Combination with RACC

On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.

Learn More

Client Highlights

Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx

On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.

Learn More

See More Leading Matters

The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.